Table 1.
Current iPSC-based clinical trials (as of 2021).
| Location | Company | Disease | Cell Type | Clinical Phase | Clinical Trial Identifier |
|---|---|---|---|---|---|
| Australia, United Kingdom | Cynata Therapeutics Limited | Graft vs. host disease | iPSC-derived mesenchymal stem cell | Phase 1 | ClinicalTrials.gov: NCT02923375 |
| United States | Fate Therapeutics | Cancer | iPSC-derived Natural Killer (NK) cell | Phase 1 | ClinicalTrials.gov: NCT03841110 |
| China | Beijing University of Chinese Medicine | Chronic heart failure | iPSC-derived cardiomyocytes | Phase 2/3 | ClinicalTrials.gov: NCT03759405 |
| Help Therapeutics | Heart failure | iPSC-derived cardiomyocytes | Phase 1/2 | ClinicalTrials.gov: NCT03763136 | |
| Japan | Kyoto University Hospital | Parkinson disease | iPSC-derived dopaminergic progenitors | Phase 1/2 | ICTRP: JPRNUMIN000033564 |
| Osaka University, Cuorips Inc. | Myocardial ischemia | iPSC-derived cardiomyocytes sheet | Phase 1 | ClinicalTrials.gov: NCT04696328 |